Updates in Breast Cancer from San Antonio
P

SABCS 2019 Highlights on Radiation Therapy in mBC: Is Radiation Therapy the Principal Curative Treatment w/ IO or Employed to Activate IO?

By Updates in Breast Cancer from San Antonio FEATURING Penny Anderson
By Updates in Breast Cancer from San Antonio FEATURING Penny Anderson
85 views
February 10, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
London Breast Meeting

London Breast Meeting 2024

Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
17:20
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
22:34
Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
12:21
Insights from 2023 SABCS

SABCS 2023 Insights: "How to Treat TNBC"

Feat. P. Sharma
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
13:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…

Feat. S. Hurvitz
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal
11:19
Adam Brufsky

HER2+ mBC: The Role of TDM-1

13:32
13th Annual Winter Breast Cancer Symposium

2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs

Feat. W. Gradishar
08:48
James Martin

2L Therapy for ER+ mBC Following CDK4/6i

08:54
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for Pat…

Feat. S. Tolaney, H. Rugo
14:54
Grace Choong

Resistance Mutations in HR+ mBC After 1L ET + CDK4/6i: Next Lines an…

19:34
Keck School of Medicine of USC

Breast Cancer Oligometastases and Beyond

Feat. S. Chmura
26:30
Insights from 2023 SABCS

SABCS 2023 Summary: "HER2+ BC Highlights From KATHERINE & H…

Feat. S. Tolaney, H. Rugo